C.R. Jackson
Biotech, healthcare, value, research analyst

What Is On The Horizon For XOMA?

Over the past 30 years, monoclonal antibody ((mAb)) therapies have revolutionized medicine. mAb therapy uses mAbs to specifically bind to target cells or proteins to stimulate the immune system to attack diseased cells. About 30 therapeutic monoclonal antibodies are marketed in the United States and Europe for a variety of indications.. mAb therapy has shown great promise as a treatment for rheumatoid arthritis, multiple sclerosuis, Alzheimer's disease, and different types of cancers.

The marketing research firm, BCC Research, found that the global market for mAbs was estimated at $44.6 billion in 2011. With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details